Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

174

Participants

Timeline

Start Date

September 29, 2023

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2027

Conditions

Estrogen-receptor-positive Breast CancerHER2/Neu-Negative Breast CancerAdvanced Breast CancervMetastatic Breast Cancer

Interventions

DRUG

elacestrant, palbociclib, abemaciclib, ribociclib

Given orally

Trial Locations (1)

RECRUITING

Northwestern University, Chicago

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER